Obesity and hepatitis infections are some reasons for the increasing rate of liver cancer deaths.
Though liver cancer is not as widespread as breast cancer or lung cancer, now this cancer is the fastest growing cause of cancer deaths in the United States.
Between 2000 and 2016, the U.S. Centers for Disease Control and Prevention (CDC) reported that liver cancer death rates increased 40 percent among women and 43 percent among men. Now the death rate for liver cancer stands at 6.3 per 100,000 women and 15 per 100,000 U.S. men.
Thus, according to the report from the CDC’s National Center for Health Statistics, liver cancer rose from being the 9th leading cause of death in the U.S. in 2000 to the 6th in 2016. Unfortunately, various leading causes of liver cancer like alcohol, obesity, and hepatitis are also on the rise in the U.S.
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
